|
|
Cardioprotective effects of sodium-glucose cotransporter SGLT2 inhibitors.
Thořová, Markéta ; Horníková, Daniela (advisor) ; Vávra, Jiří (referee)
Cardiovascular diseases are one of the most common causes of death in both non-diabetic and diabetic patients. Nowadays, a large number of drugs target cardiovascular problems. One of the very promising therapies is the use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors. SGLT2 inhibitors have gained a wide interest in the treatment of type 2 diabetes (DM2) due to their ability to lower blood glucose levels independently of insulin action. However, in addition to their main effect on glycemic control, there is increasing evidence of their beneficial effects on the cardiovascular system beyond their hypoglycaemic effects. These drugs reduce hyperglycemia, hypertension, and improve diabetic retinopathy through multiple mechanisms, many of which have not been fully explained. The main focus has been on identifying the mechanisms through which these drugs affect the heart and blood vessels, whether by reducing blood pressure, affecting cardiac cells, or improving metabolic processes in blood vessels. Key words: SGLT2, inhibitors of SGLT2, cardioprotective effect, diabetes mellitus, heart
|
guest ::
